Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin

Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Yatin, Mishra, K. C., Paliwal, Yashesh, Rangappa, Pradeep, Sinha, Sharmili, Bhapkar, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922174/
https://www.ncbi.nlm.nih.gov/pubmed/36785544
http://dx.doi.org/10.1155/2022/2668199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922174/
https://www.ncbi.nlm.nih.gov/pubmed/36785544
http://dx.doi.org/10.1155/2022/2668199

Ejemplares similares